| Literature DB >> 28960807 |
Su Golder1, Kath Wright2, Yoon K Loke3.
Abstract
Authors and indexers are increasingly including terms for adverse drug effects in the titles, abstracts, or indexing of records in MEDLINE and Embase. However, it is not clear if this is the same for studies with nondrug adverse effects data. We therefore assessed the feasibility of using adverse effects terms when searching MEDLINE or Embase to retrieve papers of nondrug adverse effects. A collection of papers that reported data on nondrug adverse effects was sought from included studies of systematic reviews. Each included study was analysed to ascertain whether the corresponding record in MEDLINE and Embase included adverse effects terms in the title, abstract, or indexing. From 9129 records screened from DARE, 30 reviews evaluating nondrug adverse effects met our inclusion criteria. From these, 635 unique papers were included in our analysis. Sensitive searches for adverse effects required generic and specific named adverse effects terms using the title, abstract, and indexing. Records relating to surgical interventions were more likely to contain adverse effects terms than records relating to nonsurgical interventions. Using any adverse effects terms in the title, abstract or indexing in MEDLINE and Embase would have identified an average of 94% of papers on surgical adverse effect interventions per systematic review and 72% of papers on nonsurgical adverse effects per systematic review. Hence, while a generic nondrug adverse effect search filter may not yet be feasible, a filter for the adverse effects of surgical interventions may be within reach.Entities:
Keywords: Adverse Effects; Complications; Information storage and retrieval; Literature searching; Medline
Mesh:
Year: 2017 PMID: 28960807 PMCID: PMC5725700 DOI: 10.1002/jrsm.1267
Source DB: PubMed Journal: Res Synth Methods ISSN: 1759-2879 Impact factor: 5.273
Figure 1Flow diagram [Colour figure can be viewed at wileyonlinelibrary.com]
Average percentage of records per systematic review with adverse effects terms
| Intervention (Number of Systematic Reviews) | Type of Adverse Effects Terms (Number of Systematic Reviews) | Title or Abstract Adverse Effects Terms (Range) | Indexing Adverse Effect Terms (Range) | Title, Abstract, or Indexing Adverse Effects Terms (Range) |
|---|---|---|---|---|
| Surgical (n = 19) | Generic (n = 19) | MEDLINE | ||
| 77% (27%‐100%) | 63% (33%‐100%) | 88% (47%‐100%) | ||
| Embase | ||||
| 78% (33%‐100%) | 73% (47%‐100%) | 89% (47%‐100%) | ||
| Specific (n = 6) | MEDLINE | |||
| 60% (11%‐100%) | 35% (0%‐82%) | 64% (11%‐100%) | ||
| Embase | ||||
| 61% (16%‐100%) | 59% (16%‐100%) | 66% (22%‐100%) | ||
| Generic or specific (n = 19) | MEDLINE and Embase | |||
| 82% (47%‐100%) | 87% (53%‐100%) | 94% (67%‐100%) | ||
| Nonsurgical (n = 11) | Generic (n = 11) | MEDLINE | ||
| 48% (10%‐97%) | 49% (5%‐97%) | 66% (40%‐100%) | ||
| Embase | ||||
| 47% (10%‐97%) | 43% (15%‐82%) | 66% (40%‐100%) | ||
| Specific (n = 1) | MEDLINE | |||
| 43% | 17% | 43% | ||
| Embase | ||||
| 39% | 45% | 55% | ||
| Generic or specific (n = 11) | MEDLINE and Embase | |||
| 50% (10%‐97%) | 60% (20%‐97%) | 72% (40%‐100%) | ||
Average percentage of records per systematic review with adverse effects terms
| Intervention (Number of Systematic Reviews) | Title or Abstract Adverse Effects Terms in MEDLINE or Embase (Range) | Indexing Adverse Effect Terms in MEDLINE or Embase (Range) | Title, Abstract, or Indexing Adverse Effects Terms in MEDLINE or Embase (Range) |
|---|---|---|---|
| Drug | 59% (49%‐69%) | 64% (54%‐76%) | 77% (69%‐83%) |
| Drug | 69% (21%‐100%) | 90% (14%‐100%) | 92% (43%‐100%) |
| Surgical (present study) (n = 19) | 82% (47%‐100%) | 87% (53%‐100%) | 94% (67%‐100%) |
| Nonsurgical (present study) (n = 11) | 50% (10%‐97%) | 60% (20%‐97%) | 72% (40%‐100%) |
Adverse effects terms in the title, abstract, or indexing of records of all included studies in MEDLINE and Embase
| Intervention | Database (Number of Records) | Title or Abstract | Indexing | Subheadings | Indexing or Subheadings | Any Search Field |
|---|---|---|---|---|---|---|
| Generic adverse effects terms | ||||||
| Surgical | MEDLINE (n = 352) | 275 (78%) | 99 (28%) | 168 (48%) | 222 (81%) | 314 (89%) |
| Embase (n = 348) | 275 (79%) | 180 (49%) | 212 (61%) | 262 (75%) | 315 (90%) | |
| Nonsurgical | MEDLINE (n = 257) | 127 (49%) | 8 (3%) | 116 (45%) | 120 (47%) | 166 (65%) |
| Embase (n = 255) | 127 (50%) | 36 (14%) | 89 (35%) | 104 (41%) | 164 (64%) | |
| Specific adverse effects | ||||||
| Surgical | MEDLINE (n = 208) | 85 (41%) | 39 (19%) | 89 (43%) | ||
| Embase (n = 208) | 88 (42%) | 81 (39%) | 94 (45%) | |||
| Nonsurgical | MEDLINE (n = 21) | 9 (43%) | 4 (19%) | 10 (48%) | ||
| Embase (n = 22) | 9 (41%) | 10 (45%) | 12 (55%) | |||
| Generic or specific adverse effects terms | ||||||
| Surgical | MEDLINE (n = 352) | 292 (83%) | 108 (31%) | 168 (48%) | 231 (65%) | 324 (92%) |
| Embase (n = 348) | 288 (83%) | 191 (55%) | 212 (61%) | 276 (79%) | 319 (92%) | |
| Nonsurgical | MEDLINE (n = 257) | 129 (50%) | 9 (4%) | 116 (45%) | 121 (47%) | 167 (65%) |
| Embase (n = 255) | 129 (51%) | 36 (14%) | 89 (35%) | 104 (41%) | 164 (64%) | |